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incidence and epidemiology
Primary lung cancer is the most common malignancy after
non-melanocytic skin cancer, and the leading cause of human
cancer deaths worldwide [1]. While it has been the most
important cause of cancer mortality in men since the 1960s, it
has equaled breast cancer as a cause of mortality in women
since the 1990s. Lung cancer is still increasing both in
prevalence and mortality worldwide. In developed countries,
the latter has begun to decline in men, reﬂecting a decrease in
smoking, and is reaching a plateau for women in most
European countries and in the United States—where lung
cancer death rates in women are approaching those of men.
Lung cancer deaths in women are expected to increase (+7%)
in the EU in 2012 [2].
Non-small-cell lung cancer (NSCLC) accounts for 80–85%
of lung cancers, while small-cell lung cancer has been
decreasing in frequency over the last two decades.
Smoking is the main cause of lung cancer, responsible for
80% of cases. The observed variations in lung cancer rates
across countries largely reﬂect differences in the stage and
degree of the tobacco epidemic, with reported crude incidence
rates between 2/100 000–80/100 000 and 1/100 000–39/100 000
for men and women, respectively. There are several other
known risk factors including exposure to asbestos, arsenic,
radon, and non-tobacco-related polycyclic aromatic
hydrocarbons, and interesting hypotheses about indoor air
pollution (e.g. coal-fueled stoves and cooking fumes) suspected
to contribute to the relatively high burden of non-smoking-
related lung cancer in women.
Prevalence of lung cancer in females without a history of
tobacco smoking is estimated to represent 19% compared with
9% of male lung carcinoma in the United States [3]. Women
are overrepresented among younger patients, raising the
question of gender-speciﬁc differences in the susceptibility to
lung carcinogens [4]. In recent times, an increase in the
proportion of NSCLC patients who are never smokers has been
observed, particularly in Asian countries [5]. These new
epidemiological data have resulted in ‘non-smoking-associated
lung cancer’ being considered a distinct disease entity, where
speciﬁc molecular and genetic tumor characteristics are being
recognized.
diagnosis
Pathological diagnosis should generally be made according to
the World Health Organization (WHO) classiﬁcation. The
International Association for the Study of Lung Cancer
(IASLC) classiﬁcation of adenocarcinoma, however, provides
new recommendations and also addresses important issues not
covered by the WHO classiﬁcation concerning small biopsy
samples and cytology. Adoption of these recommendations is
strongly advised [6]. Speciﬁc subtyping of all NSCLC is now
necessary for therapeutic decision- making and should be
carried out wherever possible. Predictive
immunohistochemistry should be used to reduce the NSCLC
not otherwise speciﬁed (NSCLC-NOS) rate to fewer than 10%
of cases diagnosed [6]. Obtaining adequate tissue material for
histological diagnosis and molecular testing is important to
allow individual treatment decisions. Re-biopsy at disease
progression should be considered [7].
Genetic alterations that are key oncogenic events have been
identiﬁed in NSCLC, with two of these to date offering the
chance of selective pathway-directed systemic therapy.
Activating (sensitizing) epidermal growth factor receptor
(EGFR) mutations are predictive for response to the EGFR
tyrosine kinase inhibitors (TKIs) geﬁtinib and erlotinib and
result, in this context, in an improved response rate (RR) and
progression-free survival (PFS) in combination with better
tolerability of treatment and a better quality of life (QoL) when
compared with chemotherapy as ﬁrst-line therapy, as
demonstrated in several randomized trials. The incidence of
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EGFR mutations in the Caucasian population is ∼10% and is
higher in never-smokers, the adenocarcinoma subtype, and in
women and is also higher in East-Asian patients. An EGFR
mutation status should be systematically analyzed—with
sequencing as a standard—in advanced NSCLC with a non-
squamous histology [II, A]. Testing is not recommended in
patients with a conﬁdent diagnosis of squamous cell
carcinoma, except in never/former light smokers (<15 packs
per year) [II, A] [8].
The EML4-ALK fusion gene, resulting from an inversion in
chromosome 2, has been identiﬁed as an oncogenic driver [9].
It is encountered more frequently in never-smokers, the
adenocarcinoma subtype and in younger patients, representing
probably ∼5% of adenocarcinoma [10]. ALK activity can be
efﬁciently targeted by the TKI crizotinib, and routine testing
for ALK rearrangements should be discussed where this drug
is available. Testing may focus upon a non-squamous histology
and never/former light smokers particularly in the absence of
an activating (sensitizing) EGFR mutation or a KRAS mutation
[II, A]. However, testing protocols may include smokers and be
carried out in parallel with EGFR/KRAS mutation analysis.
Currently, the detection of the translocation by ﬂuorescence
in situ hybridization (FISH) is standard, but
immunohistochemistry may have a role in screening out
negative cases [11].
staging and risk assessment
A complete history including smoking history and
comorbidities, weight loss, performance status (PS), and
physical examination must be recorded.
Laboratory: Standard tests including routine hematology,
renal and hepatic function, and bone biochemistry tests are
required. The routine use of serum markers—such as
carcinoembryonic antigen (CEA)—is not recommended.
radiology
• Contrast-enhanced computed tomography (CT) scan of the
chest and upper abdomen.
• Imaging of the central nervous system (CNS) is reserved for
patients with neurological symptoms or signs.
• Brain imaging should be performed in patients eligible for a
loco-regional treatment. Magnetic resonance imaging (MRI)
is more sensitive than CT scan.
• Bone scan or local bone imaging (including MRI) is required
in the presence of clinical suspicion of bony lesions not
evaluable on CT scan.
• Positron emission tomography (PET) CT scan offers the
highest sensitivity for mediastinal lymph nodes and distant
metastasis assessment.
NSCLC is staged according to the Union for International
Cancer Control (UICC) system (7th edition) and is grouped
into the stage categories shown in Tables 1 and 2. Measurement
of lesions should follow RECIST criteria v1.1 [12].
In the presence of a solitary metastatic site on imaging
studies, including pleural and pericardial effusion, efforts should
be made to obtain a cytological or histological conﬁrmation of
stage IV disease. An evaluation of resectability or the suitability
of radiotherapy with curative intent should be made in the
context of a solitary brain or adrenal lesion or oligometastatic
disease conﬁned to the lungs. This would include functional
cardio-respiratory evaluation, brain imaging, PET and, if needed
for decision-making, invasive mediastinal node evaluation.
treatment of stage IV NSCLC
The treatment strategy should take into account the histology,
molecular pathology, age, PS, comorbidities, and patient’s
preferences. Treatment decisions should ideally be discussed
within a multidisciplinary tumor board. Systemic therapy should
be offered to all stage IV NSCLC patients with a PS 0–2 [I, A].
In any stage of NSCLC, smoking cessation should be highly
encouraged because it improves the outcome.
ﬁrst-line treatment
Platinum-based combination chemotherapy prolongs survival,
improves QoL, and controls symptoms in patients with a PS 0–1.
Table 1. Tumor–node–metastasis classiﬁcation
TX Positive cytology only
T1 ≤3 cm
T1a ≤2 cm
T1b >2–3 cm
T2 Main bronchus ≥2 cm from carina invades visceral pleura, partial
atelectasis
T2a >3–5 cm
T2b >5–7 cm
T3 >7 cm; chest wall, diaphragm, pericardium, mediastinal pleura,
main bronchus <2 cm from carina, total atelectasis, separate
nodule(s) in the same lobe
T4 Mediastinum, heart, great vessels, carina, trachea, esophagus,
vertebra; separate tumor nodule(s) in a different ipsilateral lobe
N1 Ipsilateral peribronchial, ipsilateral hilar
N2 Subcarinal, ipsilateral mediastinal
N3 Contralateral mediastinal or hilar, scalene, or supraclavicular
M1 Distant metastasis
M1a Separate tumor nodule(s) in a contralateral lobe; pleural nodules or
malignant pleural, or pericardial effusion
M1b Distant metastasis
Table 2. Stage grouping
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1a,b N0 M0
Stage IB T2a N0 M0
Stage IIA T2b N0 M0
T1a,b N1 M0
T2a N1 M0
Stage IIB T2b N1 M0
T3 N0 M0
Stage IIIA T1a,b, T2a,b N2 M0
T3 N1, N2 M0
T4 N0, N1 M0
Stage IIIB T4 N2 M0
Any T N3 M0
Stage IV Any T Any N M1
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Several regimens have shown comparable efﬁcacy [13]. The
expected toxicity proﬁle should contribute to the selection of
the chemotherapy regimen, taking into account the following
conditions:
• Several meta-analyses have showed higher RRs for cisplatin
combinations when compared with carboplatin
combinations. The overall survival (OS) was signiﬁcantly
superior for cisplatin in the subgroup of non-squamous
tumors and in patients treated with third-generation
regimens, including gemcitabine and taxanes in one meta-
analysis [I, B] [14]. Cisplatin-based chemotherapy is
associated with more digestive, and neuro- and
nephrotoxicity; while hematotoxicity is more often observed
with carboplatin.
• Pemetrexed is preferred to gemcitabine in patients with non-
squamous tumors, based upon a survival beneﬁt
demonstrated in a pre-planned subgroup analysis of one
large randomized clinical trial [II, B] [15]. Pemetrexed use
should be restricted to non-squamous NSCLC in any line of
treatment [16, 17].
• According to a randomized clinical trial, bevacizumab
improves OS when combined with a paclitaxel–carboplatin
regimen in patients with non-squamous histology NSCLC
and PS 0–1 and may be offered after the exclusion of
contraindications [I, A] [18]. While its addition to
gemcitabine–cisplatin improved the RR and PFS, but not the
OS in a subsequent phase III trial [19], two meta-analyses
showed a consistent substantial improvement of the RR, PFS,
and OS for the combination of bevacizumab- and platinum-
based chemotherapy compared with platinum-based
chemotherapy in eligible patients with non-squamous
NSCLC [20, 21]. Therefore, the combination of bevacizumab
and other platinum-based chemotherapies may be
considered in eligible patients [I, A].
• A randomized phase III trial demonstrated an OS beneﬁt of
cetuximab when delivered with vinorelbine–cisplatin in
EGFR-expressing NSCLC patients with PS 0–2,
independently of histology; however, this did not lead to
regulatory approval [I, B] [22]. A subset analysis reported
that quantitative evaluation of EGFR expression by
immunohistochemistry (H-score) identiﬁed a subgroup of
patients with high EGFR expressing tumors who selectively
beneﬁted from the addition of cetuximab to chemotherapy
[23]. Prospective H-score data are, however, lacking.
• Non-platinum-based combination chemotherapy with third-
generation agents should be considered only if platinum
therapy is contraindicated. Several meta-analyses show lower
RRs for non-platinum combinations, with one of them
showing inferior survival [24] [I, A].
Timing and duration of palliative ﬁrst-line treatment:
Chemotherapy should be initiated, while the patient has a good
PS. For most patients, four cycles of chemotherapy are
recommended, notably when maintenance treatment is
considered, with a maximum of six cycles [25] [II, B].
PS ≥2 patients
Chemotherapy prolongs survival and possibly improves QoL
[26] in NSCLC patients with a PS of 2, when compared with
best supportive care (BSC) [I, B]. Single-agent chemotherapy
with gemcitabine, vinorelbine, and taxanes represents an
option [27]. Superiority of carboplatin and paclitaxel
combination over monotherapy has been identiﬁed in a
subgroup analysis within large phase III trials, with an
acceptable toxicity proﬁle [28, 29]. A prospective phase III trial
randomizing 217 patients between single-agent pemetrexed
versus carboplatin and pemetrexed was presented at ASCO
2012, showing a strong beneﬁt in OS for the platinum doublet
[30]. Therefore, platinum-based combinations may also be
considered as an alternative [II, B].
Poor PS (PS 3–4) patients should be offered BSC [II, B] in the
absence of tumors with activating (sensitizing) EGFR mutations.
elderly patients
Two randomized phase III trials established single-agent
chemotherapy as the standard of care for ﬁrst-line therapy for
clinically unselected elderly advanced NSCLC patients [27, 31]. A
recent prospective randomized trial comparing monthly
carboplatin plus weekly paclitaxel versus single-agent vinorelbine
or gemcitabine in patients aged 70–89 years with a PS of 0–2 has
reported a survival advantage for combination therapy [29].
Beneﬁt was observed across all subgroups, but increased
toxicity (notably febrile neutropenia and sepsis-related deaths)
was observed. Platinum-based chemotherapy is the preferred
option for elderly patients with PS 0–1—as well as selected PS2
—and adequate organ function, while a single-agent approach
might remain the recommended treatment of elderly unﬁt or
comorbid patients, who are more likely to present with more
treatment-related adverse events [I, B].
use of TKIs
First-line treatment with a TKI (erlotinib or geﬁtinib) should
be prescribed to patients with tumors bearing an activating
(sensitizing) EGFR mutation because of signiﬁcantly higher
RR, longer PFS, and better QoL when compared with ﬁrst-line
chemotherapy [32, 33] [I, A]. Patients with PS 3–4 may also be
offered an EGFR TKI [II, A]. Continuation treatment beyond
progression is an issue remaining to be deﬁned. In EGFR wild-
type (WT) patients, EGFR TKIs are not recommended as ﬁrst-
line therapy, being inferior to chemotherapy [I, A].
Patients with NSCLC harboring an ALK rearrangement
should be considered for crizotinib, a dual ALK and MET TKI,
during the course of their disease. Upfront comparisons with
chemotherapy are not available to date and the optimal
strategy of treatment is still to be determined [34].
brain metastasis treatment
There are several approaches to the treatment of limited-
number metastatic brain lesions, including surgery and
radiosurgery, alone or in combination with whole-brain
radiation therapy (WBRT). WBRT remains standard when
local approaches are not possible. Brain responses to
chemotherapy have been reported at a comparable level to
extracranial disease. The OS was not modiﬁed by delaying
WBRT after front-line cisplatin-based chemotherapy in a
randomized phase III trial [35] [II, B]. In patients with EGFR-
mutated NSCLC, the place of WBRT in addition to EGFR TKI,
which was shown to result in a response also at the brain level
in several reports, remains to be prospectively evaluated [36].
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Systemic therapy is therefore a reasonable option for patients with
no or relatively minor symptoms from brain metastases with
early radiotherapy intervention in the case of the development or
progression of symptoms while on treatment [II, B].
maintenance treatment
So-called ‘continuation maintenance’ and ‘switch maintenance’
therapy are terms that have been used to refer respectively to
either the use of an agent included in ﬁrst-line treatment or the
introduction of a new agent after completion of platinum-
based chemotherapy.
Two recent randomized phase III switch maintenance trials
have reported improvements in the PFS and OS with pemetrexed
or erlotinib [16, 37] versus placebo following four cycles of
platinum-based chemotherapy. In the case of pemetrexed, this
beneﬁt was seen only in patients with a non-squamous histology.
Subgroup analyses revealed the greatest beneﬁt in efﬁcacy in
patients with stable disease (SD) after induction treatment
compared with patients with a conﬁrmed response. These results
led to a label restriction for switch maintenance with erlotinib in
patients with SD after induction treatment [16, 37]. Neither trial
addressed the question of the strategy of ‘early second-line’
versus similar second-line treatment at progression. Decisions
about maintenance must take into account the histology,
response to platinum-doublet chemotherapy, remaining toxicity
after ﬁrst-line chemotherapy, PS, and patient preference [I, B].
Any patient with a tumor bearing an activating (sensitizing)
EGFR mutation should receive an EGFR TKI as maintenance, if
not received as a ﬁrst-line therapy [II, A].
Randomized trials investigating continuation maintenance
have consistently shown an improvement of the PFS but not the
OS [38]. Recently, a large phase III randomized trial of
continuation maintenance with pemetrexed versus placebo after
four induction cycles of cisplatin plus pemetrexed chemotherapy
demonstrated a PFS and OS improvement [39]. Continuing
pemetrexed following the completion of ﬁrst-line cisplatin plus
pemetrexed chemotherapy is therefore recommended in patients
with a non-squamous histology [40] [I, B].
Of note, two studies employing cetuximab and bevacizumab,
administered concomitantly to chemotherapy and further
continued as monotherapy until disease progression, have
demonstrated survival beneﬁts, but the speciﬁc role of the
maintenance phase cannot be appreciated in this context [18, 22].
second-line treatment
Patients clinically or radiologically progressing after ﬁrst-line
chemotherapy, irrespective of the administration of
maintenance or adjuvant chemotherapy, with a PS 0–2, should
be offered second-line chemotherapy. Combination regimens
failed to show any beneﬁt over single-agent treatments [41].
Single agents improve disease-related symptoms and survival.
Comparable options as the second-line therapy consist of
pemetrexed—for a non-squamous histology only [42]—or
docetaxel [43] [I, B]. Erlotinib was shown to improve the OS in
second-line or in third-line NSCLC patients of all histologies
not eligible for further chemotherapy, including patients with
PS 3 [44]. Erlotinib was shown to be equivalent to pemetrexed
or docetaxel in refractory (progression during the four cycles of
a standard platinum-based chemotherapy doublet) patients in
a randomized trial [45] [I, B]. Geﬁtinib was proved non-
inferior to docetaxel in a large randomized trial [46] with a
better toxicity proﬁle and QoL. Finally, still unpublished data
show a comparable outcome with pemetrexed or erlotinib [47].
Any patient with a tumor bearing an activating (sensitizing)
EGFR mutation should receive an EGFR TKI as second-line
therapy, if not received previously [I, A].
In the presence of an ALK rearrangement, second–third line
treatment with crizotinib should be considered if not received
as part of ﬁrst-line therapy [10, 33], although at present
approval of this compound by the European Medicines Agency
is still pending.
There is no evidence about the second-line treatment
duration, which should be individualized. Notably, treatment
may be prolonged if the disease is controlled and the toxicity
acceptable [II, B].
subsequent lines of treatment
Patients who progress after second-line chemotherapy may be
candidates for further treatment. Evidence is available only for
erlotinib, which is indicated for EGFR WT patients who have
not yet received EGFR TKIs, with PS 0–3 [II, B].
Any patient with a tumor bearing an activating (sensitizing)
EGFR mutation should receive an EGFR TKI in any line of
therapy, if not received previously [I, A].
role of minimally invasive procedures in stage IV
NSCLC
Endoscopy has a role to play in palliative care, notably in case
of symptomatic major airway obstruction or post-obstructive
infection, where endoscopic debulking by laser, cryotherapy or
stent placement may be helpful [III; C]. Endoscopy is useful in
the diagnosis and treatment (endobronchial or by guiding
endovascular embolization) of hemoptysis [III; C)].
Vascular stenting might be useful in NSCLC-related superior
vena cava compression [II; B].
role of palliative surgery in stage IV NSCLC
Recurrent pleural effusions can be managed by pleurodesis.
The preferred sclerosing agent is talc, which is more effective
than bleomycin or tetracycline [48] [II, B]; thoracoscopic
insufﬂation with talc (poudrage) is more effective than talc
slurry sclerosis [49] [II, B].
Surgery might be necessary in case of signiﬁcant local
complications related to the primary tumor or metastasis, like
abscess, uncontrolled massive hemoptysis, spinal cord
compression, or pathologic bone fracture.
role of radiotherapy
Radiotherapy plays a major role in symptom control in case of
bone and brain metastases. It is also effective in treating pain
related to chest wall, soft tissue, or neural invasion. Neurological
symptoms from spinal compression can be relieved by early
radiotherapy. Radiotherapy is indicated in cases of hemoptysis,
symptomatic airway compression or obstruction, and following
CNS and, sometimes, bone surgery [II; B].
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role of biphosphonate administration
Zoledronic acid reduces skeletal-related events (SREs;
pathologic fracture, radiation to or surgery of bone, or spinal
cord compression) and is recommended in stage IV bone
metastatic disease [50] [II; B].
Denosumab is not inferior [I; A] and shows a trend toward
superiority, to zoledronic acid in lung cancer in terms of SRE
prevention [51] [II; B].
role of early palliative-care intervention
Early palliative-care intervention is recommended, in parallel
with standard oncologic care [I; A]. Evidence demonstrating
that palliative-care interventions signiﬁcantly improve the QoL
remains scarce. A randomized trial evaluating the impact of
introducing specialized palliative care early after the diagnosis
of stage IV disease on the patient’s QoL in ambulatory patients
was able to show an improvement in the QoL and mood, a
reduction in aggressive treatment, and an improvement in
median survival [52].
response evaluation
Response evaluation is recommended after two to three cycles
of chemotherapy using the same initial radiographic
investigation that demonstrated tumor lesions. Follow-up with
PET is not routinely recommended, due to its high sensitivity
and relatively low speciﬁcity. Measurements and response
reporting should follow RECIST 1.1 criteria [12]. However, the
adequacy of RECIST in evaluating the response to EGFR or
ALK TKI in respective genetically driven NSCLCs is debatable.
treatment of oligometastatic NSCLC
Stage IV NSCLC patients presenting with solitary metastases, if
localized to brain, adrenals, or lung, can be treated with
curative intent. This requires individual assessment, taking into
account the timing of appearance of metastasis relative to the
primary tumor (metachronous being of better prognosis than
synchronous disease [53]), patient PS and comorbidities, as
well as local extension of the primary tumor.
• In the case of solitary brain metastasis, surgical resection
followed by WBRT or alternatively radiosurgery with or without
WBRT might be beneﬁcial. WBRT after surgery prolongs the
OS [II; A] [54], while this beneﬁt was not reproduced after
radiosurgery [55] [II; B]. Radiosurgery combined with WBRT is
superior to WBRT alone in patients presenting with up to three
brain metastases [56]. Further treatment options include
surgical resection of lung primary tumor combined with
systemic chemotherapy [II; B], or deﬁnitive chemoradiotherapy,
preferred in the case of locally advanced primary, such as
solitary station N2 disease [57] [III; B].
• In cases of solitary—histological proven—adrenal metastasis,
prolonged survival after resection of adrenal and the primary
tumor has been suggested in selected patients [II; B] [58].
• Solitary lesions in the contralateral lung should, in most
cases, be considered as synchronous secondary primary
tumors, and treated, if possible, with surgery and adjuvant
chemotherapy if indicated, deﬁnitive radiotherapy or
chemoradiotherapy [II;A].
follow-up
The optimal approach to post-treatment management of
patients with NSCLC, including the role of radiological
evaluation, is controversial, with very limited literature available.
Owing to the aggressive nature of this disease, generally
close follow-up, at least every 6 weeks after the ﬁrst-line
therapy, is advised but should also depend on individual re-
treatment options [III; B]. Given the clear beneﬁts of second-
line therapy in patients who presented an initial response to
ﬁrst-line chemotherapy and maintain a good PS, radiological
follow-up should be considered every 6–12 weeks to allow for
an early initiation of second-line therapy.
note
Summary of recommendations is provided in Table 3.
Table 3. Summary of recommendations
Topic Recommendations
Diagnosis • Pathological diagnosis should be made according to the WHO classiﬁcation and the IASLC classiﬁcation of adenocarcinoma.
• Speciﬁc subtyping of all NSCLCs is necessary for therapeutic decision-making and should be carried out wherever possible.
• Predictive immunohistochemistry should be used to reduce the NSCLC-NOS rate to fewer than 10% of cases diagnosed.
• Adequate tissue material for histological diagnosis and molecular testing should be obtained to allow individual treatment
decisions.
• Re-biopsy at disease progression should be considered.
• EGFR mutation status should be systematically analyzed—with sequencing as a standard—in advanced NSCLC with a non-
squamous histology [II, A].
• Testing is not recommended in patients with a conﬁdent diagnosis of squamous cell carcinoma, except in never/former light
smokers (<15 packs per year) [II, A].
• ALK activity can be efﬁciently targeted by the TKI crizotinib, and routine testing for ALK rearrangements should be discussed
where this drug is available.
• Testing may focus upon a non-squamous histology and never/former light smokers especially in the absence of an activating
(sensitizing) EGFR mutation or a KRAS mutation [II, A].
• Detection of the translocation by FISH is standard, but immunohistochemistry may have a role in screening out negative cases.
Continued
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Table 3. Continued
Topic Recommendations
Staging and risk
assessment
• A complete history including smoking history and comorbidities, weight loss, PS and physical examination must be recorded.
• Laboratory: standard tests including routine hematology, renal and hepatic function, and bone biochemistry tests are required.
Routine use of serum markers—such as CEA—is not recommended.
• Contrast-enhanced CT scan of the chest and upper abdomen should be performed.
• Imaging of CNS is reserved for patients with neurological symptoms or signs.
• Brain imaging should be performed in patients eligible for a loco-regional treatment. Magnetic resonance imaging (MRI) is
more sensitive than CT scan.
• Bone scan or local bone imaging is required in the presence of clinical suspicion of bony lesions not evaluable on a CT scan.
• PET CT scan offers the highest sensitivity and is advised for mediastinal lymph nodes and distant metastasis assessment.
• NSCLC is staged according to the UICC system (7th edition) and is grouped into the stage categories shown in Tables 1 and 2.
Measurement of lesions should follow RECIST criteria v1.1.
• In the presence of a solitary metastatic site on imaging studies, efforts should be made to obtain a cytological or histological
conﬁrmation of stage IV disease.
• An evaluation of resectability or the suitability of radiotherapy with curative intent should be made in the context of a solitary
brain or adrenal lesion or oligometastatic disease conﬁned to the lungs: cardio-respiratory evaluation, brain imaging, PET and, if
needed for decision-making, invasive mediastinal node evaluation.
Treatment strategy • The treatment strategy should take into account the histology, molecular pathology, age, PS, comorbidities, and patient’s
preferences.
• Treatment decisions should be discussed within a multidisciplinary tumor board.
• Systemic therapy should be offered to all stage IV patients with PS 0–2 [I, A].
• In any stage of NSCLC, smoking cessation should be highly encouraged because it improves the outcome.
First-line treatment • In the subgroup of non-squamous tumors and in patients treated with third-generation regimens, including gemcitabine and
taxanes, cisplatin should be the treatment of choice [I, B].
• Pemetrexed is preferred to gemcitabine in patients with non-squamous tumors [II, B]. Pemetrexed use should be restricted to
non-squamous NSCLC in any line of treatment.
• Bevacizumab combined with a paclitaxel–carboplatin regimen may be offered to patients with non-squamous histology NSCLC
and PS0–1 after exclusion of contraindications [I, A].
• The combination of bevacizumab and other platinum based chemotherapies may be considered in eligible patients with non-
squamous NSCLC [I, A].
• Non-platinum-based combination chemotherapy with third-generation agents should be considered only if platinum therapy is
contraindicated [I, A].
• The timing and duration of palliative ﬁrst-line treatment: chemotherapy should be initiated while the patient has a good PS. For
most patients, four cycles of chemotherapy are recommended, with a maximum of six cycles [II, B].
PS ≥2 patients:
• Chemotherapy prolongs survival and possibly improves the QoL in NSCLC patients with a PS of 2, when compared with BSC
[I, B]. Single-agent chemotherapy with gemcitabine, vinorelbine, and taxanes represents an option. Platinum-based
combinations may also be considered as an alternative [II, B].
• Poor PS (3–4) patients should be offered best supportive care [II, B] in the absence of tumors with activating (sensitizing) EGFR
mutations.
Elderly patients:
• Single-agent chemotherapy is the standard of care for ﬁrst-line therapy for clinically unselected elderly advanced NSCLC
patients.
• A survival advantage has been seen for combination therapy in patients aged 70–89 with PS0-2.
• Platinum-based chemotherapy is the preferred option for elderly patients with PS 0–1—as well as selected PS2—and adequate
organ function. A single-agent approach might remain the recommended treatment of elderly unﬁt or comorbid patients who
are more likely to present with more treatment-related adverse events [I, B].
Use of TKIs:
• First-line treatment with a TKI (erlotinib or geﬁtinib) should be prescribed to patients with tumors bearing an activating
(sensitizing) EGFR mutation [I, A].
• Patients with EGFR mutation and PS 3–4 may also be offered an EGFR TKI [II, A].
• In EGFR WT patients, EGFR TKIs are not recommended as ﬁrst-line therapy, being inferior to chemotherapy [I, A].
• Patients with NSCLC harboring an ALK rearrangement should be considered for crizotinib, a dual ALK and MET TKI, during
the course of their disease.
Continued
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Table 3. Continued
Topic Recommendations
Brain metastases treatment:
• WBRT remains the standard treatment of limited-number metastatic brain lesions when local approaches are not possible.
• Delaying WBRT after front-line cisplatin-based chemotherapy does not modify the OS according to a randomized phase III trial.
• Systemic therapy is a reasonable option for patients with no or relatively minor symptoms from brain metastases with early
radiotherapy intervention in the case of the development or progression of symptoms while on treatment [II, B].
Maintenance treatment • In patients with a non-squamous histology, improvements in PFS and OS were observed with pemetrexed switch maintenance
versus placebo following four cycles of platinum-based chemotheraphy.
• Switch maintenance with erlotinib versus placebo demonstrated PFS and OS beneﬁt in all histologies, with a greatest beneﬁt in
efﬁcacy in patients with stable disease (SD) after induction treatment leading to a label restriction for such patients.
• Decisions about maintenance must take into account the histology, response to platinum-doublet chemotherapy, remaining
toxicity after ﬁrst-line chemotherapy, PS, and patient preference [I, B].
• Any patient with a tumor bearing an activating (sensitizing) EGFR mutation should receive an EGFR TKI as maintenance, if
not received as the ﬁrst-line therapy [II, A].
• Continuing pemetrexed following completion of ﬁrst-line cisplatin plus pemetrexed chemotherapy is recommended in patients
with a non-squamous histology [I, B].
Second-line treatment • Patients clinically or radiologically progressing after ﬁrst-line chemotherapy with PS 0–2 should be offered second-line
chemotherapy.
• Comparable options as the second-line therapy consist of pemetrexed—for a non-squamous histology only—or docetaxel [I, B].
Erlotinib is an additional option in EGFR WT patients with PS 0–3 [II, B].
• Any patient with a tumor bearing an activating (sensitizing) EGFR mutation should receive an EGFR TKI as the second-line
therapy, if not received previously [I, A].
• Treatment may be prolonged if the disease is controlled and the toxicity acceptable [II, B].
Subsequent lines of
treatment
• Erlotinib is indicated for EGFR WT patients who have not yet received EGFR TKIs, with PS 0–3 [II, B].
• Any patient with a tumor bearing an activating (sensitizing) EGFR mutation should receive an EGFR TKI in any line of
therapy, if not received previously [I, A].
Role of minimally-
invasive procedures in
stage IV NSCLC
• In case of symptomatic major airway obstruction or post-obstructive infection, endoscopic debulking by laser, cryotherapy, or
stent placement may be helpful [III; C].
• Endoscopy is useful in the diagnosis and treatment (endobronchial or by guiding endovascular embolization) of hemoptysis [III; C].
• Vascular stenting might be useful in NSCLC-related superior vena cava compression [II; B].
Role of palliative surgery
in stage IV NSCLC
• Recurrent pleural effusions can be managed by pleurodesis.
• The preferred sclerosing agent is talc, which is more effective than bleomycin or tetracycline [II, B]; thoracoscopic insufﬂation
with talc (poudrage) is more effective than talc slurry sclerosis [II, B].
Role of radiotherapy • Radiotherapy plays a major role in symptom control in the case of bone and brain metastases and is also effective in treating
pain related to chest wall, soft tissue, or neural invasion.
• Neurological symptoms from spinal compression can be relieved by early radiotherapy.
• Radiotherapy is indicated in cases of hemoptysis, symptomatic airway compression or obstruction, and following CNS and,
sometimes, bone surgery [II; B].
Role of bisphosphonate
administration
• Zoledronic acid reduces SRE (pathologic fracture, radiation/surgery to bone, or spinal cord compression) and is recommended
in stage IV bone metastatic disease [II; B].
• Denosumab is not inferior [I; A], and shows a trend toward superiority, to zoledronic acid in lung cancer in terms of SRE
prevention [II; B].
Role of palliative-care
early intervention
Early palliative-care intervention is recommended, in parallel with standard oncologic care [I; A].
Response evaluation • Response evaluation is recommended after two to three cycles of chemotherapy using the same initial radiographic investigation
which demonstrated tumor lesions.
• Follow-up with PET is not routinely recommended, due to its high sensitivity and relatively low speciﬁcity.
• Measurements and response reporting should follow RECIST 1.1 criteria. However, the adequacy of RECIST in evaluating the
response to EGFR or ALK TKI in respective genetically driven NSCLC is debatable.
Continued
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